Biopharma

Human medicines European public assessment report (EPAR): Prasugrel Viatris (previously Prasugrel Mylan), prasugrel, Date of authorisation: 15/05/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 25, 2025 0

Human medicines European public assessment report (EPAR): Prasugrel Viatris (pre...

Merck bets $200M on a new type of heart pill

Merck bets $200M on a new type of heart pill

Mar 25, 2025 0

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitiv...

Human medicines European public assessment report (EPAR): EndolucinBeta, lutetium (177 Lu) chloride, Date of authorisation: 06/07/2016, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 25, 2025 0

Human medicines European public assessment report (EPAR): EndolucinBeta, lutetiu...

Human medicines European public assessment report (EPAR): Sugammadex Fresenius Kabi, sugammadex, Date of authorisation: 15/07/2022, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 25, 2025 0

Human medicines European public assessment report (EPAR): Sugammadex Fresenius K...

Axsome touts success of phase 3 trial of Sunosi in ADHD, adding to 'string of recent wins'

Axsome touts success of phase 3 trial of Sunosi in ADHD...

Mar 25, 2025 0

Fast-rising New York City central nervous system specialist Axsome has scored in...

How 23andMe’s gene-testing dream turned recessive

How 23andMe’s gene-testing dream turned recessive

Mar 25, 2025 0

The biotech group created a revolutionary technology but it never hit on a susta...

Annual list of grants 2024

Mar 25, 2025 0

Annual list of grants 2024

Second EMA / Alliance for Regenerative Medicine bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 8 May 2025, 14:00 (CEST) to 8 May 2025, 16:00 (CEST)

Second EMA / Alliance for Regenerative Medicine bilater...

Mar 25, 2025 0

Second EMA / Alliance for Regenerative Medicine bilateral meeting, Online, Europ...

Eisai lays out road map to blockbuster sales projections for Leqembi's 'milestone' 2027 year

Eisai lays out road map to blockbuster sales projection...

Mar 25, 2025 0

Eisai ran a simulation projecting that Leqembi sales for fiscal year 2027, which...

CTIS newsflash - 25 March 2025

Mar 25, 2025 0

CTIS newsflash - 25 March 2025

STAT+: Net prices for medicines inched up in last year’s fourth quarter after falling a year ago, analysis finds

STAT+: Net prices for medicines inched up in last year’...

Mar 25, 2025 0

Net prices that health plans paid for medicines rose a modest 0.4% in the fourth...

Contractors WuXi Bio, WuXi XDC eye continued growth after logging solid performances in 2024

Contractors WuXi Bio, WuXi XDC eye continued growth aft...

Mar 25, 2025 0

Shortly after WuXi AppTec offered an upbeat outlook for 2025, other WuXi compani...

How health insurers are using AI today

How health insurers are using AI today

Mar 25, 2025 0

In this edition of STAT Health Tech: How health insurers are using AI for effici...

Trump again threatens tariffs on pharmaceuticals in 'not too distant' future

Trump again threatens tariffs on pharmaceuticals in 'no...

Mar 25, 2025 0

After threatening a month ago to impose “25% or higher” tariffs on foreign-made ...

Does the kidney transplant system need to change?

Does the kidney transplant system need to change?

Mar 25, 2025 0

Americans dying avoidable deaths, reforming the kidney transplant system, a new ...

EMEA-002945-PIP03-23

EMEA-002945-PIP03-23

Mar 25, 2025 0

EMEA-002945-PIP03-23

EMEA-002886-PIP02-23

EMEA-002886-PIP02-23

Mar 25, 2025 0

EMEA-002886-PIP02-23

Guidance on the application of the amended Variations Regulation from 1 January 2025

Guidance on the application of the amended Variations R...

Mar 25, 2025 0

Guidance on the application of the amended Variations Regulation from 1 January ...

Notifying a change of marketing status

Notifying a change of marketing status

Mar 25, 2025 0

Notifying a change of marketing status

European Medicines Agency procedural advice on recommen...

Mar 25, 2025 0

European Medicines Agency procedural advice on recommendations on unforeseen var...

Periodic safety update reports (PSURs)

Periodic safety update reports (PSURs)

Mar 25, 2025 0

Periodic safety update reports (PSURs)

STAT+: Pharmalittle: We’re reading about NIH removing scientific advisers, GSK’s shingles shot, and more

STAT+: Pharmalittle: We’re reading about NIH removing s...

Mar 25, 2025 0

Prominent outside scientists who help the NIH evaluate its internal research pro...

Post-authorisation safety studies (PASS)

Post-authorisation safety studies (PASS)

Mar 25, 2025 0

Post-authorisation safety studies (PASS)

Human medicines European public assessment report (EPAR): Sugammadex Amomed, sugammadex, Date of authorisation: 10/01/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 25, 2025 0

Human medicines European public assessment report (EPAR): Sugammadex Amomed, sug...

72
73
74
75
76

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.